05 Jan 2017
Albumedix to present at the 35th Annual J.P. Morgan Healthcare Conference
Press Release: Copenhagen, Denmark – January 5th, 2017 – Albumedix, a science-driven biotechnology company focused on albumin-based therapeutics, announced today that Peter Rosholm, Chief Executive Officer of Albumedix, will present a corporate overview at the J.P. Morgan 35th Annual Healthcare Conference 2017 to be held January 9-12, 2017, at the Westin St. Francis Hotel in San Francisco, CA.
The presentation is scheduled for Thursday, January 12, 2017 at 11:30 a.m. (Pacific Time) and will take place at the Westin, Union Square the Elisabeth A room with the subsequent Q&A session from 12:00-12:30 PM in the Sussex room.
You can join the presentation via a live webcasting which will furthermore be available on-demand for 90 days afterwards.
Albumedix A/S is a global, science-driven biotechnology company focused on developing superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. At Albumedix we are Dedicated to Better Health and partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with our products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. We are as passionate about albumin and albumin enabled therapies today as we were when we started 30 years ago. Albumedix is headquartered in Kgs. Lyngby, Denmark, with manufacturing and R&D in Nottingham, England, and 100 people all committed to improving patient quality of life. Albumedix is a fully owned subsidiary of Novozymes A/S.
Company contact & Investor relation:
Jonas Skjodt Moller
Director, Marketing & Business Development
+45 4446 2227
Communication & Media relation:
+44 (0)1606 889194